Acuitybio Overview
- Founded
- 2008
- Status
- Private
- Employees
- 4
- Latest Deal Type
- Angel
- Latest Deal Amount
- $175K
- Investors
- 3
Acuitybio General Information
Description
Developer of bio-compatible and biodegradable drug-eluting surgical products intended to commercialize novel polymer drug delivery technologies. The company's products are implemented with safety and efficacy in preclinical models, long-term targeted delivery of therapeutic levels of paclitaxel to areas at highest risk for harboring residual cancer cells and can be applied to additional indications besides lung cancer, enabling surgeons to administer during initial tumor removal surgery and prevent recurrence.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Surgical Devices
Primary Office
- 321 Walnut Street
- Suite 300
- Newton, MA 02460
- United States
+1 (617) 000-0000
Acuitybio Timeline
Acuitybio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Angel (individual) | 10-Feb-2020 | $175K | 00.000 | Completed | Pre-Clinical Trials | |
| 5. Angel (individual) | 13-Nov-2017 | 00.000 | 00.000 | 000.00 | Completed | Generating Revenue |
| 4. Grant | Completed | Generating Revenue | ||||
| 3. Grant | 01-Jul-2013 | 00000 | Completed | Generating Revenue | ||
| 2. Grant | 16-Sep-2011 | $1.4M | Completed | Generating Revenue | ||
| 1. Grant | 01-Jan-2008 | Completed | Startup |
Acuitybio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.00 |
Acuitybio Executive Team (6)
Acuitybio Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Eyal Ron Ph.D | Self | Board Member & Advisor | 000 0000 |
| John Schwartz Ph.D | Acuitybio | Co-Founder, Board Member, Chairman & Chief Executive Officer | 000 0000 |
| Karen English | Acuitybio | Chief Financial Officer & Board Member | 000 0000 |
| Mark Grinstaff Ph.D | Self | Co-Founder & Board Member | 000 0000 |
| Peter Lui | Acuitybio | Board Member | 000 0000 |
Acuitybio Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAcuitybio Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | ||
| National Cancer Institute | Government | 000 0000 | 000000 0 | ||
| Internal Revenue Service | Government | 000 0000 | 000000 0 |